Biomarkers of aHSCT
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Multiple Sclerosis, Relapsing-Remitting. Basic parameters: from 16 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
Overview
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. Over the last 20 years more than 1800 patients with MS have been treated in Europe with high levels of success. It may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. There is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. Whilst aHSCT is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment. Unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs. This study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing aHSCT and compare it to those receiving disease modifying treatment. This study will therefore further the understanding of biomarkers of aHSCT to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.
Primary outcome measures
- Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment. [Time frame: 24 months]
- Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment. [Time frame: 24 months]
Secondary outcome measures (7)
- Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips. [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS) [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA) [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC) [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36) [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to symbol digit modality test (SDMT) [Time frame: 24 months]
- Evaluate immunological disease response and the duration of response to aHSCT according to Karnofsky performance status [Time frame: 24 months]
Eligibility criteria
Inclusion criteria
- Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm).
- Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm).
- Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up.
- Able to understand English and provide informed consent.
Exclusion criteria
1\. Inability to provide informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
United Kingdom · 1 center
- Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield
Identifiers
NCT: NCT06195800 · STH22343